https://www.live-feeds.com/feed/incyte-pancreatic-cancer-medicine-induces-lasting-tumor-responses-company-says-at-esmoContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/incyte-pancreatic-cancer-medicine-induces-lasting-tumor-responses-company-says-at-esmohttps://www.live-feeds.com/feed/incyte-pancreatic-cancer-medicine-induces-lasting-tumor-responses-company-says-at-esmo#u163309Fri, 30 Oct 2026 08:57:01 +0000Incyte presented new data at the ESMO congress showing that its pancreatic cancer medicine, INCB161734, induces lasting tumor responses when combined with chemotherapy in patients with KRAS G12D-mutated pancreatic ductal adenocarcinoma. The company reported that these findings strengthen its late-stage gastrointestinal cancer programs. Incyte also views its position in the KRAS G12D pancreatic cancer drug race as neck and neck with competitor RevMed. These developments were showcased alongside other gastrointestinal portfolio highlights during the annual European Society for Medical Oncology m